|
2025
|
G/S
|
Pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutica... |
|
|
G/S
|
Educational services in the field of cell therapy, namely, providing educational resources in the... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cancer and tumors, and autoimmune diseases and d... |
|
|
Invention
|
Chimeric transmembrane proteins and uses thereof.
Provided herein are chimeric transmembrane pro... |
|
|
Invention
|
Predictive markers for immunotherapy.
The disclosure relates to methods of prognosis and therapy... |
|
|
Invention
|
Predictive markers for immunotherapy. The disclosure relates to methods of prognosis and therapy,... |
|
|
Invention
|
Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting... |
|
|
Invention
|
Chimeric antigen receptor t cell therapy.
The disclosure provides methods of treating a malignan... |
|
|
Invention
|
Methods for generating engineered lymphocytes with enriched t memory stem cells.
Provided herein... |
|
|
Invention
|
Methods for generating engineered lymphocytes with enriched t memory stem cells. Provided herein ... |
|
|
Invention
|
Methods and systems for scheduling a patient-specific immunotherapy procedure.
A method and syst... |
|
2024
|
Invention
|
Chimeric antigen and t cell receptors and methods of use.
Provided is a chimeric antigen recepto... |
|
|
Invention
|
Systems and methods for upregulation of low-density lipoprotein receptor (ldl-r) expression. The ... |
|
|
Invention
|
Systems and methods for upregulation of low-density lipoprotein receptor (ldl-r) expression.
The... |
|
|
Invention
|
Antigen binding molecules and methods of use thereof.
Isolated antigen binding molecules that sp... |
|
|
Invention
|
Cd70 binding molecules and methods of use thereof.
The disclosure provides anti-CD70 antibodies,... |
|
|
G/S
|
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of cancer; pha... |
|
|
G/S
|
Pharmaceutical preparations, namely, pharmaceutical
preparations for the treatment of cancer; ph... |
|
|
Invention
|
Factors for optimizing immunotherapy efficacy.
The disclosure relates to methods for predicting ... |
|
|
Invention
|
Factors for optimizing immunotherapy efficacy. The disclosure relates to methods for predicting a... |
|
|
Invention
|
Chimeric receptor t cell treatment using characteristics of the tumor microenvironment.
The disc... |
|
|
Invention
|
T cells with improved functionality.
Immune cell engineered to inhibit the endogenous expression... |
|
|
Invention
|
Tgf-beta receptors and methods of use.
Provided herein are engineered receptors that include an ... |
|
|
Invention
|
Apparatuses, systems, and methods for storing and transporting a temperature sensitive material. ... |
|
|
G/S
|
Pharmaceutical preparations for use in the treatment of cancer and hematological diseases and dis... |
|
|
Invention
|
Prostate cancer chimeric antigen receptors.
Provided are antibodies, fragments thereof, chimeric... |
|
|
Invention
|
Allogenic therapeutic cells with reduced risk of immune rejection.
The present disclosure provid... |
|
|
Invention
|
Allogenic therapeutic cells with reduced risk of immune rejection. The present disclosure provide... |
|
|
Invention
|
Systems and methods for detecting suspended particles in fluids. The present disclosure describes... |
|
|
Invention
|
Impact of tumor microenvironment on efficacy of immunotherapy. The disclosure relates to prognosi... |
|
|
Invention
|
Systems and methods for detecting suspended particles in fluids.
The present disclosure describe... |
|
|
Invention
|
Impact of tumor microenvironment on efficacy of immunotherapy.
The disclosure relates to methods... |
|
|
Invention
|
Antigen binding molecules and methods of use.
The present disclosure describes antigen binding m... |
|
|
Invention
|
Antigen binding molecules and methods of use. The present disclosure describes antigen binding mo... |
|
2023
|
Invention
|
Methods for producing autologous t cells useful to treat b cell malignancies and other cancers an... |
|
|
Invention
|
Flow cytometric method for characterization of t-cell impurities.
Compositions and methods for f... |
|
|
Invention
|
Factors for optimizing immunotherapy. The disclosure relates to methods for treating a malignancy... |
|
|
Invention
|
Efficacy and durable response of immunotherapy.
Provided herein are methods for preparing, produ... |
|
|
Invention
|
Expedited administration of engineered lymphocytes.
Provided herein are methods for expedited ma... |
|
|
Invention
|
Expedited administration of engineered lymphocytes. Provided herein are methods for expedited man... |
|
|
Invention
|
Improving efficacy and durable response of immunotherapy. Provided herein are methods for prepari... |
|
|
Invention
|
Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same.... |
|
|
Invention
|
Novel cd19 binders, car-t constructs comprising the same, and methods of using the same. The disc... |
|
|
Invention
|
Cd19 binders, car-t constructs comprising the same, and methods of using the same.
The disclosur... |
|
|
Invention
|
Large scale car-t immune cell manufacturing method utilizing lentiviral vector transfection.
The... |
|
|
Invention
|
New large scale car-t immune cell manufacturing method utilizing lentiviral vector transfection. ... |
|
|
Invention
|
Systems and methods for shipping cryogenically-frozen materials.
Embodiments of the disclosure r... |
|
|
Invention
|
Novel systems for shipping cryogenically frozen materials. Embodiments of the disclosure relate t... |
|
|
Invention
|
Immune cell function.
The present disclosure relates to the field of cell therapy, and more spec... |
|
|
Invention
|
Diagnostic methods for t cell therapy.
The invention provides methods of increasing the efficacy... |
|
2022
|
Invention
|
Dnvsig3 and dnvsig8 receptors and methods of using the same.
Described are dominant-negative rec... |
